Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food and Rabeprazole on ZN-A-1041 PK in Healthy Participants
NCT07329972Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ZN-A-1041 in breast cancer (8 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration and 2 more. Started Nov 2025; status: completed.
02
Drugs
ZN-A-1041
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07329972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07329972.